BDX — Becton, Dickinson and Company stock price, charts and financials
QT54Becton, Dickinson and CompanyBecton, Dickinson and Company (NYSE: BDX) is a Healthcare company in the Medical - Instruments & Supplies industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | S&P 500 | P/E | 54.16 | EPS (ttm) | 3.32 | Insider Own | 0.27% | Shs Outstand | 275.54M | Perf Week | -3.91% |
| Market Cap | 49.54B | Forward P/E | 13.53 | EPS next Y | 13.29 | Insider Trans | -1.62% | Shs Float | 274.94M | Perf Month | 0.09% |
| Enterprise Value | 65.64B | PEG | 8.23 | EPS next Q | 4.06 | Inst Own | - | Short Float | 3.41% | Perf Quarter | 18.26% |
| Income | 941.00M | P/S | 2.38 | EPS this Y | 281.64% | Inst Trans | - | Short Ratio | 3.92 | Perf Half Y | 9.71% |
| Sales | 20.84B | P/B | 2.03 | EPS next Y | 4.91% | ROA | 1.85% | Short Interest | 9.37M | Perf YTD | 17.85% |
| Book/sh | 88.62 | P/C | 69.88 | EPS next 5Y | 6.58% | ROE | 3.79% | 52W High | 193.06 -6.87% | Perf Year | 19.38% |
| Cash/sh | 2.57 | P/FCF | 19.53 | EPS past 3/5Y | -0.28% 16.56% | ROIC | 3.72% | 52W Low | 127.59 40.92% | Perf 3Y | -17.87% |
| Dividend Est. | 4.20 (2.34%) | EV/EBITDA | 16.84 | Sales past 3/5Y | 4.99% 6.32% | Gross Margin | 46.12% | Volatility | 2.30% 2.14% | Perf 5Y | -6.86% |
| Dividend TTM | 3.98 (2.21%) | EV/Sales | 3.15 | EPS Y/Y TTM | -43.34% | Oper. Margin | 9.83% | ATR (14) | 4.37 | Perf 10Y | 32.25% |
| Dividend Ex-Date | Sep 09, 2026 | Quick Ratio | 0.51 | Sales Y/Y TTM | 3.28% | Profit Margin | 4.52% | RSI (14) | 47.72 | Recom | 2.56 |
| Dividend Gr. 3/5Y | 8.36% 7.36% | Current Ratio | 0.87 | EPS Q/Q | -13.43% | SMA20 | -3.37% | Beta | 0.22 | Target Price | 186.88 |
| Payout | 187.14% | Debt/Eq | 0.76 | Sales Q/Q | -9.55% | SMA50 | 5.17% | Rel Volume | 0.72 | Prev Close | 179.10 |
| Employees | 72,000 | LT Debt/Eq | 0.69 | Earnings | Nov 05 | SMA200 | 12.31% | Avg Volume | 2.10M | Price | 179.80 |
| IPO Date | Feb 21, 1973 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 4.38% 0.90% | Net Debt/EBITDA | 4.13 | Volume | 1,517,288 | Change | 0.39% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-13-26 | Reiterated | RBC Capital | Sector Perform | $180 → $190 |
| Aug-07-26 | Reiterated | Stifel Nicolaus | Buy | $175 → $195 |
| Aug-07-26 | Reiterated | RBC Capital | Sector Perform | $175 → $180 |
| Aug-06-26 | Reiterated | Jefferies | Buy | $190 → $210 |
| Jul-28-26 | Initiated | UBS | Buy | $190 |
| Jul-06-26 | Reiterated | Evercore ISI Group | Outperform | $290 → $180 |
| May-11-26 | Reiterated | Barclays | Overweight | $202 → $204 |
| Apr-17-26 | Reiterated | Piper Sandler | Neutral | $170 → $159 |
| Apr-14-26 | Reiterated | RBC Capital | Sector Perform | $195 → $175 |
| Apr-10-26 | Resumed | Goldman Sachs | Neutral | $274 → $167 |
Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 9/30/2025 | FY 2024 9/30/2024 | FY 2023 9/30/2023 | FY 2022 9/30/2022 | FY 2021 9/30/2021 | FY 2020 9/30/2020 | FY 2019 9/30/2019 | FY 2018 9/30/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 20,839 | 21,839 | 20,178 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 11,228 | 11,915 | 11,053 | — | — | — | — | — | — | |
| Gross Profit | 9,611 | 9,924 | 9,125 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 5,272 | 5,277 | 4,857 | — | — | — | — | — | — | |
| Research and Development | 1,147 | 1,264 | 1,190 | — | — | — | — | — | — | |
| Other Operating Expense | 1,146 | 806 | 681 | — | — | — | — | — | — | |
| Operating Income | 2,048 | 2,578 | 2,397 | — | — | — | — | — | — | |
| Interest Expense | 543 | 613 | 528 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 85 | -83 | 136 | — | — | — | — | — | — | |
| Net Income Before Taxes | 1,590 | 1,882 | 2,005 | — | — | — | — | — | — | |
| Income Taxes | 301 | 204 | 300 | — | — | — | — | — | — | |
| Consolidated Net Income | 941 | 1,678 | 1,705 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 1,289 | 1,678 | 1,705 | — | — | — | — | — | — | |
| Net Income | 941 | 1,678 | 1,705 | — | — | — | — | — | — | |
| EPS (Recurring) | 3.32 | 5.84 | 5.88 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 3.32 | 5.84 | 5.88 | — | — | — | — | — | — | |
| EPS (Diluted) | 3.32 | 5.83 | 5.86 | — | — | — | — | — | — | |
| EBITDA | 3,897 | 4,957 | 4,819 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 54.16 | 25.24 | 32.34 | — | — | — | — | — | — | |
| Price To Sales Ratio | 2.37 | 1.93 | 2.72 | — | — | — | — | — | — | |
| Gross Margin | 46.12 | 45.44 | 45.22 | — | — | — | — | — | — | |
| Operating Margin | 9.83 | 11.80 | 11.88 | — | — | — | — | — | — | |
| Net Margin | 4.52 | 7.68 | 8.45 | — | — | — | — | — | — | |
| Shares Outstanding | 275 | 287 | 290 | — | — | — | — | — | — | |
| Market Capitalization | 49,445 | 42,232 | 54,967 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Feld Michael | EVP, Chief Revenue Officer | Aug 26 '26 | Sale | 188.49 | 165 | 31,101 | 19,720 | Aug 27 |
| Polen Thomas E Jr | Chairman, CEO and President | Aug 13 '26 | Option Exercise | 167.25 | 43,278 | 7,238,246 | 153,441 | Aug 14 |
| Polen Thomas E Jr | Chairman, CEO and President | Aug 13 '26 | Sale | 185.00 | 4,152 | 768,120 | 110,163 | Aug 14 |
| Goette Roland | EVP and President, EMEA | Aug 11 '26 | Sale | 180.84 | 2,438 | 440,888 | 14,856 | Aug 12 |
| Feld Michael | EVP, Chief Revenue Officer | Jul 27 '26 | Sale | 157.13 | 75 | 11,785 | 20,934 | Jul 28 |
| Feld Michael | EVP, Chief Revenue Officer | Jun 26 '26 | Sale | 152.80 | 75 | 11,460 | 21,009 | Jun 26 |
| Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | Jun 24 '26 | Sale | 145.66 | 1,100 | 160,226 | 13,172 | Jun 25 |
| Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | Jun 10 '26 | Sale | 151.48 | 1,100 | 166,628 | 14,272 | Jun 11 |
| Polen Thomas E Jr | Chairman, CEO and President | Jun 01 '26 | Option Exercise | 126.16 | 20,209 | 2,549,567 | 125,680 | Jun 03 |
| Polen Thomas E Jr | Chairman, CEO and President | Jun 01 '26 | Sale | 146.35 | 2,764 | 404,511 | 110,163 | Jun 03 |
| Feld Michael | EVP, Chief Revenue Officer | May 26 '26 | Sale | 147.35 | 75 | 11,051 | 21,084 | May 27 |
| Feld Michael | EVP, Chief Revenue Officer | Apr 27 '26 | Sale | 151.94 | 74 | 11,244 | 21,159 | Apr 28 |
| Feld Michael | EVP, Chief Revenue Officer | Mar 26 '26 | Sale | 156.83 | 75 | 11,762 | 21,233 | Mar 27 |
| Feld Michael | EVP, Chief Revenue Officer | Feb 26 '26 | Sale | 181.84 | 75 | 13,638 | 21,308 | Feb 27 |
| SCOTT BERTRAM L | Director | Feb 18 '26 | Sale | 182.61 | 953 | 174,027 | 36,763 | Feb 18 |